RT Journal Article
T1 Meroxest improves the prognosis of immunocompetent C57BL/6 mice with allografts of E0771 mouse breast tumor cells.
A1 Carrasco, Esther
A1 Garrido, Jose Manuel
A1 Álvarez, Pablo Juan
A1 Álvarez-Manzaneda, Enrique
A1 Chahboun, Rachid
A1 Messouri, Ibtissam
A1 Melguizo, Consolación
A1 Aránega, Antonia
A1 Rodríguez-Serrano, Fernando
K1 Ki67
K1 breast cancer
K1 in vivo
K1 merosesquiterpene
K1 vascular endothelial growth factor
AB Recently, we have reported the antitumor properties of a new family of synthetic merosesquiterpenes, among which meroxest is highlighted, since it has high activity and specificity for ER+ breast cancer cells. In this paper, we characterize allografts of ER+ E0771 mouse breast tumor cells in immunocompetent C57BL/6 mice, and also analyze the effect of meroxest on the prognosis of the disease. Twenty female C57BL/6 mice were injected with 106 E0771 cells. Once the tumors reached the appropriate size, the mice were divided into two groups, one control and another treated orally with 15 mg/kg of meroxest. After 20 days, tumor samples were taken for histopathological study and for determination of the expression of the prognostic markers Ki67 and vascular endothelial growth factor (VEGF) by immunofluorescence. In sections stained with hematoxylin-eosin, we observed that tumors have a well-defined capsule enclosing E0771 tumor cells. The central area of tumors contains necrotic regions with leukocyte infiltration. Meroxest treatment significantly reduces tumor size (68%, p  Meroxest improves the prognosis of mice since it reduces leukocyte infiltration, and decreases the expression of Ki67 and VEGF markers. Consequently, the merosesquiterpene could become a useful antiangiogenic drug in the treatment of breast cancer. These results encourage us to deepen the study of meroxest, in order to find more evidence that supports the convenience of its evaluation in a clinical study or trial.
SN 1734-1922
YR 2016
FD 2016-03-31
LK http://hdl.handle.net/10668/10498
UL http://hdl.handle.net/10668/10498
LA en
DS RISalud
RD Apr 10, 2025